TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Most patients with colorectal cancer die as a result of the disease spreading to other organs. However, no prevalent mutations have been associated with metastatic colorectal cancers. Instead, particular features of the tumour microenvironment, such as lack of T-cell infiltration, low type 1 T-helper cell (T H 1) activity and reduced immune cytotoxicity or increased TGFβ levels predict adverse outcomes in patients with colorectal cancer. Here we analyse the interplay between genetic alterations and the tumour microenvironment by crossing mice bearing conditional alleles of four main colorectal cancer mutations in intestinal stem cells. Quadruple-mutant mice developed metastatic intestinal tumours that display key hallmarks of human microsatellite-stable colorectal cancers, including low mutational burden, T-cell exclusion and TGFβ-activated stroma. Inhibition of the PD-1-PD-L1 immune checkpoint provoked a limited response in this model system. By contrast, inhibition of TGFβ unleashed a potent and enduring cytotoxic T-cell response against tumour cells that prevented metastasis. In mice with progressive liver metastatic disease, blockade of TGFβ signalling rendered tumours susceptible to anti-PD-1-PD-L1 therapy. Our data show that increased TGFβ in the tumour microenvironment represents a primary mechanism of immune evasion that promotes T-cell exclusion and blocks acquisition of the T H 1-effector phenotype. Immunotherapies directed against TGFβ signalling may therefore have broad applications in treating patients with advanced colorectal cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Blockade of the TGFβ signaling pathway promotes enough T cell infiltration to make tumors sensitive to PD-1 therapy [39].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [39]
In the citing paper
“Cell analysis of human and mouse CRC specimens showed that CAF is a major contributor to TGF-β production [39].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [39]
In the citing paper
“It has been demonstrated in a variety of tumor models, including CRC models, that activation of CAF may induce PD-1 and CTLA-4 expression on relevant immune cells, which leads to tumor insensitivity to immunotherapy or recurrence [39,304,305,306].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [39]
In the citing paper
“A landmark study from 2018 demonstrated that TGF-β contributes to immune exclusion in colorectal liver metastasis and that inhibition of the TGF-β receptor 1 using the drug galunisertib enhanced tumorous infiltration with T cells, inhibited outgrowth of liver metastases and synergised with anti-PD-L1 therapy to eradicate established lesions.161”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [161]
In the citing paper
“leading to the proposition that combined TGFβ targeting and immune checkpoint blockade may represent an attractive therapeutic strategy for CMS4 colorectal cancer (34).”
From Clinical Challenges of Consensus Molecular Subtype CMS4 Colon Cancer in the Era of Precision Medicine (2024) · cites this paper as [34]
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Fitting Linear Mixed-Effects Models Using lme4
Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015) · Journal of Statistical Software · doi:10.18637/jss.v067.i01 · Cited by 86,835
lmerTest Package: Tests in Linear Mixed Effects Models
Kuznetsova, A., Brockhoff, P. B., & Christensen, R. H. B. (2017) · Journal of Statistical Software · doi:10.18637/jss.v082.i13 · Cited by 24,346
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
Data Analysis Using Regression and Multilevel/Hierarchical Models
Gelman, A., & Hill, J. (2006) · doi:10.1017/cbo9780511790942 · Cited by 13,597
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Cited by
Items 601–700 of 1,002
Gao, Y., Men, K., Pan, C., Li, J., Wu, J., Chen, X., Lei, S., Gao, X., & Duan, X. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s319092 · Cited by 47
Salvucci, M., Crawford, N., Stott, K. J., Bullman, S., Longley, D. B., & Prehn, J. H. M. (2021) · Gut · doi:10.1136/gutjnl-2021-325193 · Cited by 58
“…EMT via NOTCH or WNT has shown limited success in the clinic, 48 microenvironment remodelling to reverse immunosuppression by inhibiting CXCL12 49 or promoting T-cell infiltration 50 or function via engineered oncolytic adenovirus, 51 has shown promising results in reducing metastasis formation.”
He, R., Lao, Y., Yu, W., Zhang, X., Jiang, M., & Zhu, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.764618 · Cited by 48
Mouillet-Richard, S., Cazelles, A., Sroussi, M., Gallois, C., Taieb, J., & Laurent-Puig, P. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3964 · Cited by 43
Molecular imaging to enlighten cancer immunotherapies and underlying involved processes
van der Veen, E. L., Bensch, F., Glaudemans, A. W. J. M., Hooge, M. N. L., & de Vries, E. G. E. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.007 · Cited by 46
Qu, Y., Yang, H., Li, S., Li, L., Li, Y., & Wang, D. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123927 · Cited by 48
Obstacles to T cell migration in the tumor microenvironment
Nicolas-Boluda, A., & Donnadieu, E. (2019) · Comparative Immunology, Microbiology and Infectious Diseases · doi:10.1016/j.cimid.2018.12.006 · Cited by 43
Suzuki, S., Ogawa, T., Sano, R., Takahara, T., Inukai, D., Satou, A., Tsuchida, H., Yoshikawa, K., Ueda, R., & Tsuzuki, T. (2020) · Cancer Science · doi:10.1111/cas.14422 · Cited by 46
Kok, S. Y., Oshima, H., Takahashi, K., Nakayama, M., 村上, 和., Ueda, H. R., Miyazono, K., & Oshima, M. (2021) · Nature Communications · doi:10.1038/s41467-021-21160-0 · Cited by 51
Kondo, Y., Suzuki, S., Takahara, T., Ono, S., Goto, M., Miyabe, S., Sugita, Y., Ogawa, T., Ito, H., Satou, A., et al. (2021) · Cancer Science · doi:10.1111/cas.15081 · Cited by 45
What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Wang, Q., Xie, B., Liu, S., Shi, Y., Tao, Y., Xiao, D., & Wang, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.773168 · Cited by 51
Harryvan, T. J., Visser, M., de Bruin, L., Plug, L. G., Griffioen, L., Mulder, A., van Veelen, P. A., van Noort, G. J. V. D. H., Jongsma, M. L. M., Meeuwsen, M. H., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003591 · Cited by 50
Emerging Biomaterials Imaging Antitumor Immune Response
Ma, X., Zhang, M., Wang, J., Zhang, T., Xue, P., Kang, Y., Sun, Z., & Xu, Z. (2022) · Advanced Materials · doi:10.1002/adma.202204034 · Cited by 43
Peng, K., Zhang, Y., Liu, D.-Y., & Chen, J. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02862-5 · Cited by 45
Advancing translational research for colorectal immuno-oncology
Thomas, E., Wright, J. A., Blake, S. J., Page, A. J., Worthley, D. L., & Woods, S. L. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02392-x · Cited by 53
Yuan, J. X., Li, Y., Zhang, H., Beeraka, N. M., Zhang, D., Wang, Q., Wang, M., Hemanth Vikram, P. R., Sethi, G., & Wang, G. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117714 · Cited by 52
RetractedThe Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC
Marwitz, S., Turkowski, K., Nitschkowski, D., Weigert, A., Brandenburg, J., Reiling, N., Thomas, M., Reck, M., Drömann, D., Seeger, W., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01550 · Cited by 44
“Pirfenidone Reduced the Tumor Growth and Improved Tumor Infiltration by Immune Cells Since we observed potent effects of Pirfenidone on NSCLC cell proliferation and viability as well as an impact on TGFβ pathway, we next investigated the effect in an in vivo model using the murine adenocarcinoma cell line LLC1 as rece…”
BackgroundGut γδ T cells as guardians, disruptors, and instigators of cancer
Suzuki, T., Hayman, L., Kilbey, A., Edwards, J., & Coffelt, S. B. (2020) · Immunological Reviews · doi:10.1111/imr.12916 · Cited by 45
The tumour immune microenvironment in oesophageal cancer
Davern, M., Donlon, N. E., Power, R. F., Hayes, C., King, R., Dunne, M. R., & Reynolds, J. V. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01331-y · Cited by 50
“A clear role for TGF-β in mediating T exclusion from tumours has been established in CRC and urothelial cancer where, blockade of TGF-β induced T cell infiltration in immune-excluded tumour types and synergised with PD-L1 blockade in murine studies.(123,124) However, it remains to be determined whether TFG-β plays a r…”
BackgroundXu, Y., Hao, X., Ren, Y., Xu, Q., Liu, X., Song, S., & Wang, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1063423 · Cited by 50
Xie, Q., Liu, X., Liu, R., Pan, J., & Liang, J. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02166-w · Cited by 49
Stamm, H., Wellbrock, J., & Fiedler, W. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9770-7 · Cited by 45
Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer
Janssen, J. B. E., Medema, J. P., Gootjes, E. C., Tauriello, D. V. F., & Verheul, H. M. W. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102433 · Cited by 47
Self-citationZhang, H., Wang, Z., Dai, Z., Wu, W., Cao, H., Li, S., Zhang, N., & Cheng, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.694490 · Cited by 52
“RS compared with a low ICP score, and these stroma signatures have previously been proved to facilitate the immune escape of cancer (52).”
Zhang, H., Chen, L., Zhao, Y., Luo, N., Shi, J., Xu, S., Ma, L., Wang, M., Gu, M., Mu, C., et al. (2023) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2023.100796 · Cited by 49
Targeting Cancer‐Associated Fibroblasts: Eliminate or Reprogram?
Yamazaki, M., & Ishimoto, T. (2025) · Cancer Science · doi:10.1111/cas.16443 · Cited by 46
Kather, J. N., Charoentong, P., Suarez‐Carmona, M., Herpel, E., Klupp, F., Ulrich, A. B., Schneider, M., Zoernig, I., Luedde, T., Jaeger, D., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1126 · Cited by 43
Endo, E., Okayama, H., Saito, K., Nakajima, S., Yamada, L., Ujiie, D., Kase, K., Fujita, S., Endo, H., Sakamoto, W., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0308 · Cited by 40
Jensen, C., Nissen, N. I., von Arenstorff, C. S., Karsdal, M. A., & Willumsen, N. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02133-z · Cited by 45
“Moreover, coadministration of anti-PD-L1 and anti-TGF-β antibodies in both a mammary carcinoma mouse model and in colon carcinoma mouse models have been shown to induce T cell infiltration into the tumor, which was associated with an anti-tumor response [11, 64, 65].”
BackgroundClinical Application of Adaptive Immune Therapy in MSS Colorectal Cancer Patients
Wang, D., Zhang, H., Xiang, T., & Wang, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.762341 · Cited by 40
“It has been reported that TGF-b can promote T-cell exclusion and block the acquisition of the Th1 effector phenotype (70).”
BackgroundBiomarkers for predicting the efficacy of immune checkpoint inhibitors
Wang, C., Wang, H.-N., & Wang, L. (2022) · Journal of Cancer · doi:10.7150/jca.65012 · Cited by 44
“TGF-β inhibitors can increase the sensitivity of anti PD-1/PD-L1 therapy in the mouse models of progressive liver metastatic diseases, which may be due to TGF-β inhibition resulting in an effective and long-lasting cytotoxic T-cell response to tumor cells [114].”
BackgroundFlum, M., Dicks, S., Teng, Y.-H., Schrempp, M., Nyström, A., Boerries, M., & Hecht, A. (2022) · Oncogene · doi:10.1038/s41388-022-02190-4 · Cited by 46
“TGFβ receptors and Smad4, a key TF in canonical TGFβ signaling, are frequently inactivated to boost experimental metastasis in animal models [18, 20–24], and it was proposed that TGFβ signaling acts on nonneoplastic stromal rather than cancer cells to promote metastases formation [25, 26].”
BackgroundBenoit, A., Vogin, G., Duhem, C., Berchem, G., & Janji, B. (2023) · Cells · doi:10.3390/cells12131787 · Cited by 39
“For instance, transforming growth factor-β (TGF-β) contributes to the lack of T cell infiltration and low response to anti-PD-1/PD-L1 immunotherapy in metastatic urothelial cancer [41] and colon cancer metastasis [42].”
BackgroundCurrent and emerging concepts for systemic treatment of metastatic colorectal cancer
Steup, C., Kennel, K. B., Neurath, M. F., Fichtner-Feigl, S., & Greten, F. R. (2025) · Gut · doi:10.1136/gutjnl-2025-335412 · Cited by 39
Barlési, F., Isambert, N., Felip, E., Cho, B. C., Lee, D. H., Peguero, J. A., Jérusalem, G., Penel, N., Saâda-Bouzid, E., Garrido, P., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac253 · Cited by 46
Li, K., Liu, W., Yu, H., Chen, J., Tang, W., Wang, J., Qi, M., Sun, Y., Xu, X., Zhang, J., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci170490 · Cited by 49
Hou, W. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1602452 · Cited by 45
Sandberg, T. P., Oosting, J., van Pelt, G. W., Mesker, W. E., Tollenaar, R. A. E. M., & Morreau, H. (2018) · Oncotarget · doi:10.18632/oncotarget.25845 · Cited by 38
Unlocking the Mystery of the Therapeutic Effects of Chinese Medicine on Cancer
Liu, S.-H., Chen, P.-S., Huang, C., Hung, Y.-T., Lee, M.-Y., Lin, W., Lin, Y., & Lee, A. Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.601785 · Cited by 43
Minimal Residual Disease, Metastasis and Immunity
Badia-Ramentol, J., Linares, J., Gómez‐Llonín, A., & Calon, A. (2021) · Biomolecules · doi:10.3390/biom11020130 · Cited by 44
“For instance, TGF-β may be secreted by metastatic initiating cells in order to modulate T cell exclusion in CRC, consequently allowing efficient metastatic initiation by avoiding TIL immunosurveillance [86,88,176].”
BackgroundSelf-citationTumor Immune Evasion Induced by Dysregulation of Erythroid Progenitor Cells Development
Grzywa, T. M., Justyniarska, M., Nowis, D., & Gołąb, J. (2021) · Cancers · doi:10.3390/cancers13040870 · Cited by 43
Zimmer, C. L., Filipovic, I., Cornillet, M., O’Rourke, C. J., Berglin, L., Jansson, H., Sun, D., Strauss, O., Hertwig, L., Johansson, H., et al. (2021) · Hepatology · doi:10.1002/hep.32222 · Cited by 41
“TGFβ is known to up- regulate CD103,[42] and thus increased CD103 expression on tumor- infiltrating MAIT cells might be a sign of a TGFβ- driven signature of the tumor microenvironment.[43] However, this occurred without a readily detectable increase in PD1 expression on intratumoral MAIT cells, unlike what has been o…”
ResultThe cellular and molecular basis of CD69 function in anti-tumor immunity
Koyama‐Nasu, R., Wang, Y., Hasegawa, I., Endo, Y., Nakayama, T., & Kimura, M. Y. (2022) · International Immunology · doi:10.1093/intimm/dxac024 · Cited by 49
ITGB1 as a prognostic biomarker correlated with immune suppression in gastric cancer
Gu, W., Sun, H., Zhang, M., Mo, S., Tan, C., Ni, S., Yang, Z., Wang, Y., Sheng, W., & Wang, L. (2022) · Cancer Medicine · doi:10.1002/cam4.5042 · Cited by 47
Morris, V. K., Overman, M. J., Lam, M., Parseghian, C. M., Johnson, B., Dasari, A., Raghav, K., Kee, B. K., Huey, R., Wolff, R. A., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0194 · Cited by 38
Vienot, A., Pallandre, J., Renaude, E., Viot, J., Bouard, A., Spehner, L., Kroemer, M., Abdeljaoued, S., van der Woning, B., de Haard, H., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2144669 · Cited by 40
“Previous studies showed that TGF-β1 blockade enables cytotoxic lymphocyte homing in the tumor of mice treated with anti-PD-1.(1,2) Here, we first observed that TGF-β1 production remained detectable in tumors treated with ICD-inducing chemotherapy ± ICI.”
Huang, J., Tsang, W. Y., Li, Z., & Guan, X. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.07.001 · Cited by 44
Luo, L., Zhang, B., Tao, F., Chen, Z., Ye, Q., Zhao, X., & Wu, J. (2023) · ACS Nano · doi:10.1021/acsnano.3c00295 · Cited by 40
Huang, H., Zhu, X., Yu, Y., Li, Z., Yang, Y., Xia, L., & Lü, S. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05456-5 · Cited by 47
Su, X., Li, J., Xu, X., Ye, Y., Wang, C., Pang, G., Liu, W., Liu, A., Zhao, C., & Hao, X. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05552-6 · Cited by 49
Combating Drug Resistance in Colorectal Cancer Using Herbal Medicines
Lee, G., Lee, J., Son, C., & Lee, N. (2020) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-020-3425-8 · Cited by 40
Navarro, R., Tapia‐Galisteo, A., Martín‐García, L., Tarín, C., Corbacho, C., Goméz-López, G., Sánchez‐Tirado, E., Campuzano, S., González-Cortés, A., Yáñez‐Sedeño, P., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12779 · Cited by 39
Sadeghirad, H., Bazaz, S. R., Monkman, J. H., Warkiani, M. E., Rezaei, N., O'Byrne, K. J., & Kulasinghe, A. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1215 · Cited by 40
Pei, X., Zhang, X., Zhang, L., Yuan, M., Sun, L., Yu, F., Wang, B., Zhao, J., He, H., & Yang, V. C.-M. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.129774 · Cited by 41
Effects of 1p/19q Codeletion on Immune Phenotype in Low Grade Glioma
Lv, L., Zhang, Y., Zhao, Y., Wei, Q., Zhao, Y., & Yi, Q. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.704344 · Cited by 47
Abdulrahman, Z., Santegoets, S. J. A. M., Sturm, G., Charoentong, P., Ijsselsteijn, M. E., Somarakis, A., Höllt, T., Finotello, F., Trajanoski, Z., van Egmond, S. L., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004346 · Cited by 41
“It also provides a rational foundation for combinations of T cell-stimulating agents 6 55 56 with strategies focusing on the identified resistance mechanisms, for example, cotargeting M2-like macrophages, 57 TGF-β , 58 and/or angiogenesis.”
Corgnac, S., Damei, I., Gros, G., Caidi, A., Terry, S., Chouaïb, S., Deloger, M., & Mami‐Chouaib, F. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004527 · Cited by 44
Devan, A. R., Pavithran, K., Nair, B., Murali, M., & Nath, L. R. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i36.5250 · Cited by 40
TGF-β-dependent lymphoid tissue residency of stem-like T cells limits response to tumor vaccine
Li, G., Srinivasan, S., Wang, L., Ma, C., Guo, K., Xiao, W., Liao, W., Mishra, S., Zhang, X., Qiu, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33768-x · Cited by 46
PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity
Gu, Y. J., Lin, X., Dong, Y., Wood, G. A., Seidah, N. G., Werstuck, G. H., Major, P. P., Bonert, M., Kapoor, A., & Tang, D. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02584-y · Cited by 54
Mutual regulation of TGFβ-induced oncogenic EMT, cell cycle progression and the DDR
Schuhwerk, H., & Brabletz, T. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.11.009 · Cited by 42
Five latent factors underlie response to immunotherapy
Usset, J. L., Huber, A. R., Andrianova, M. A., Batlle, E., Carles, J., Cuppen, E. P. J. G., Élez, E., Felip, E., Gómez-Rey, M., Giacco, D. L., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01899-0 · Cited by 45
“Thus, we computed the mean expression of 255 gene sets (225 representing all Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and cancer hallmarks obtained from the Molecular Signatures Database (MSigDB) 25,26 and 30 collected from the literature 12,27,28 ; Supplementary Table 2, Fig.”
Self-citationPrecision-based modeling approaches for necrotizing enterocolitis
Kovler, M. L., Sodhi, C. P., & Hackam, D. J. (2020) · Disease Models & Mechanisms · doi:10.1242/dmm.044388 · Cited by 36
MicroRNA signatures associated with lymph node metastasis in intramucosal gastric cancer
Kim, S., Bae, W. J., Ahn, J. M., Heo, J. H., Kim, K., Choi, K. W., Sung, C. O., & Lee, D. (2020) · Modern Pathology · doi:10.1038/s41379-020-00681-x · Cited by 37
Wang, X., Ji, Q., Yan, X., Lian, B., Si, L., Chi, Z., Sheng, X., Kong, Y., Mao, L., Bai, X., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.546604 · Cited by 40
Wang, S., Hossain, M. Z., Han, T., Shinozuka, K., Suzuki, T., Kuwana, A., & Kobayashi, H. (2020) · ACS Omega · doi:10.1021/acsomega.0c04429 · Cited by 42
Liver regeneration and liver metastasis
Riddiough, G. E., Jalal, Q., Perini, M. V., & Majeed, A. W. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.05.012 · Cited by 43
Wu, Q., Zhang, W., Wang, Y., Min, Q., Zhang, H., Dong, D., & Zhan, Q. (2021) · 癌症:英文版 · doi:10.1002/cac2.12203 · Cited by 38
Liu, Z., Qi, T., Li, X., Yao, Y., Othmane, B., Chen, J., Zu, X., Ou, Z., & Hu, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.791924 · Cited by 42
Mellone, M., Piotrowska, K., Venturi, G., James, L., Bzura, A., Lopez, M. A., James, S., Wang, C., Ellis, M. J., Hanley, C. J., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0435 · Cited by 39
Zhang, J., Zhang, Z., Huang, Z., Li, M., Yang, F., Wu, Z., Guo, Q., Mei, X., Lü, B., Wang, C., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.006 · Cited by 37
Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1
Beach, C., MacLean, D., Majorova, D., Melemenidis, S., Nambiar, D. K., Kim, R. K., Valbuena, G. N., Guglietta, S., Krieg, C., Darvish-Damavandi, M., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci168277 · Cited by 40
“The composition of the tumor microenvironment (TME) affects treatment responses in cancer (1–3).”
BackgroundCross-Talk Between Cancer and Its Cellular Environment—A Role in Cancer Progression
Turlej, E., Domaradzka, A., Radzka, J., Drulis‐Fajdasz, D., Kulbacka, J., & Gizak, A. (2025) · Cells · doi:10.3390/cells14060403 · Cited by 50
Tumour vessel remodelling: new opportunities in cancer treatment
Ganß, R. (2020) · Vascular Biology · doi:10.1530/vb-19-0032 · Cited by 42
Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer
Furukawa, K., Nagano, T., TACHIHARA, M. Y., Yamamoto, M., & Nishimura, Y. (2020) · Molecules · doi:10.3390/molecules25173900 · Cited by 40
Perspectives on Immunotherapy of Metastatic Colorectal Cancer
Dai, Y., Zhao, W., Yue, L., Dai, X., Rong, D., Wu, F., Gu, J., & Qian, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.659964 · Cited by 39
Yang, M., Li, D., Jiang, Z., Li, C., Ji, S., Sun, J. P., Chang, Y., Ruan, S., Wang, Z., Liang, R., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0924 · Cited by 52
RAS signaling and immune cells: a sinister crosstalk in the tumor microenvironment
Liu, Y., Xie, B., & Chen, Q. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04486-9 · Cited by 44
“Coincidentally, KRAS-mutated MSS CRC mouse models also showed strong stromal activation, with transforming growth factor-β (TGF-β) signaling thought to be dominant [46].”
BackgroundSingh, D., & Siddique, H. R. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10141-y · Cited by 41
“Additionally, it also promotes T-cell exclusion from tumors, preventing them from recognizing and attacking cancer cells [41, 42].”
InfluentialMuta, Y., Linares, J. F., Martínez-Ordóñez, A., Durán, Á., Cid-Diaz, T., Kinoshita, H., Zhang, X., Han, Q., Nakanishi, Y., Nakanishi, N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43690-5 · Cited by 38
Enhancing anti-tumor immunity of natural killer cells through targeting IL-15R signaling
Nikolić, I., Cursons, J., Shields, B., Chappaz, S., Sudholz, H., Meng, X., Constantinescu, P., Vijayakumaran, R., D’Angelo, M. E., Foroutan, M., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.05.011 · Cited by 49
Haro, M., & Oršulić, S. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00098 · Cited by 42
Eide, P. W., Eilertsen, I. A., Sveen, A., & Lothe, R. A. (2019) · International Journal of Cancer · doi:10.1002/ijc.31998 · Cited by 39
“TGF-β suppression is critical in intestinal differentiation(42) and is in the CRCsetting associated with metastatic capabilities(43) and tumor Tcell exclusion.(44) MIR31 outlier expression was not associated with T-cell exclusion in our study, however, interferons are known to be produced by most cell types and modula…”
BackgroundUckun, F. M., Qazi, S., Hwang, L., & Trieu, V. N. (2019) · Cancers · doi:10.3390/cancers11121892 · Cited by 40
Chromatin Remodeling of Colorectal Cancer Liver Metastasis is Mediated by an HGF‐PU.1‐DPP4 Axis
Wang, L., Wang, E., Balcazar, J. P., Wu, Z., Xiang, K., Wang, Y., Huang, Q., Negrete, M., Chen, K., Li, W., et al. (2021) · Advanced Science · doi:10.1002/advs.202004673 · Cited by 41
Zhu, X., Fang, H., Gladysz, K., Barbour, J. A., & Wong, J. W. H. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.003 · Cited by 35
Chen, Y., Yu, Z., Lv, M., Cai, Z., Zou, Y., Lan, P., Wu, X., & Gao, F. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00402-3 · Cited by 43
Parkes, E. E., Savage, K. I., Lioe, T. F., Boyd, C., Halliday, S. R., Walker, S. M., Lowry, K., Knight, L. A., Buckley, N. E., Grogan, A., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01599-0 · Cited by 37
Ortiz‐Cuaran, S., Swalduz, A., Foy, J., Marteau, S., Morel, A., Fauvet, F., Souza, G. D., Michon, L., Boussageon, M., Gadot, N., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.03.038 · Cited by 42
Español‐Rego, M., Fernández-Martos, C., Élez, E., Foguet, C., Pedrosa, L., Rodríguez, N., Ruiz‐Casado, A., Pineda, E., Cid, J., Cabezón, R., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03283-5 · Cited by 36
Recent progress in nanocarrier-based drug delivery systems for antitumour metastasis
Peng, S., Yuan, X., Li, H., Wei, Y.-N., Zhou, B., Ding, G., & Bai, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115259 · Cited by 38
Vanpouille-Box, C., & Formenti, S. C. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.03.002 · Cited by 35
Xu, C., Xia, Y., Zhang, B., Drokow, E. K., Li, H., Xu, S., Wang, Z., Wang, S., Jin, P., Fang, T., et al. (2023) · MedComm · doi:10.1002/mco2.242 · Cited by 42
Grainyhead-like-2 confers NK-sensitivity through interactions with epigenetic modifiers
MacFawn, I., Wilson, H. E., Selth, L. A., Leighton, I. A., Serebriiskii, I. G., Bleackley, R. C., Elzamzamy, O. M., Farris, J. C., Pifer, P. M., Richer, J. K., et al. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.11.006 · Cited by 31
“…effects of IFN-γ, antigen loss, expression of immune checkpoint ligands, depletion of tryptophan or the expression of TGF-β (Aqbi et al., 2018; Chen et al., 2014; Dunn et al., 2006; Gao et al., 2016; Knutson et al., 2006; Minn and Wherry, 2016; Patel et al., 2017; Tauriello et al., 2018).”
BackgroundAdvani, S., & Kopetz, S. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25441 · Cited by 36
“For example, M7824 a fusion protein consisting of avelumab (anti‐PD‐L1) bound to the extracellular domain of human transforming growth factor β receptor type II (TGF‐βRII) is being investigated among mCRC patients that are identified as consensus molecular subtype 4 on the basis of the high TGF‐β expression and immune…”
MethodChen, H., Ye, Y., Yang, Y. F., Zhong, M., Gu, L., Han, Z., Qiu, J., Liu, Z., Qiu, X., & Zhuang, G. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00276-7 · Cited by 34
Cancer Cells Resistance Shaping by Tumor Infiltrating Myeloid Cells
Domagala, M., Laplagne, C., Leveque, E., Laurent, C., Fournié, J., Espinosa, É., & Poupot, M. (2021) · Cancers · doi:10.3390/cancers13020165 · Cited by 38
“NFκB signaling in hematopoietic progenitors [115] as well as the tumor-derived TGF-β can inhibit antigen uptake [116].”
BackgroundLiu, J., Huang, Z., Chen, H., Qin, S., Chen, Y., Jiang, J., Zhang, Z., Luo, M., Ye, Q., Xie, N., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01713-9 · Cited by 40
Chi, A., He, X., Hou, L., Nguyen, N. P., Zhu, G., Cameron, R. B., & Lee, J. M. (2021) · Cancers · doi:10.3390/cancers13122924 · Cited by 37
Targeting Versican as a Potential Immunotherapeutic Strategy in the Treatment of Cancer
Hirani, P., Gauthier, V., Allen, C. E., Wight, T. N., & Pearce, O. M. T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.712807 · Cited by 36
Metadata
- Authors
- Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., Byrom, D., Matarin, J. A., Calon, A., Rivas, E. I., Nebreda, A. R., Riera, A., Attolini, C. S.-O., & Batlle, E.
- Affiliations
- Institute for Research in Biomedicine (ES)
- Universitat Autònoma de Barcelona (ES)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Batlle, Eduard
- ORCID
- Venue
- Nature
- Published
- 2018-02
- Volume
- 554
- Issue
- 7693
- Pages
- 538-543
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2788975052
- Cited by
- 1,851
- References
- 43
- Citations by year
- 2026: 193 · 2025: 186 · 2024: 159 · 2023: 211 · 2022: 280 · 2021: 305 · 2020: 247 · 2019: 176 · 2018: 94
- FWCI
- 77.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- TGF-beta signaling, colorectal cancer metastasis, immune evasion, T-cell exclusion, tumor microenvironment, immune checkpoint inhibitors, TGF-beta inhibition, liver metastasis, microsatellite stable colorectal cancer, genetically engineered mouse models, organoid transplantation, combination immunotherapy
- MeSH terms
- Alleles, Animals, Cell Differentiation, Colonic Neoplasms, Disease Models, Animal, Drug Synergism, Female, Humans, Immunotherapy, Intestinal Mucosa, Intestines, Liver Neoplasms, Male, Mutation, Neoplasm Metastasis, Stem Cells, T-Lymphocytes, Cytotoxic, Transforming Growth Factor beta, Th1 Cells, Mice, Immune Evasion, Tumor Microenvironment, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.